DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Kaletra (Lopinavir / Ritonavir) - Summary

 
 



KALETRA SUMMARY

KALETRA®
(lopinavir/ritonavir) capsules
(lopinavir/ritonavir) oral solution

KALETRA (lopinavir/ritonavir) is a co-formulation of lopinavir and ritonavir. Lopinavir is an inhibitor of the HIV protease. As co-formulated in KALETRA, ritonavir inhibits the CYP3A-mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir.

KALETRA is indicated in combination with other antiretroviral agents for the treatment of HIV-infection.
See all Kaletra indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Kaletra (Lopinavir / Ritonavir)

Entire female reproductive tract is susceptible to HIV infection, suggests study of vaginal virus challenge in rhesus macaques
Source: HIV / AIDS News From Medical News Today [2014.10.09]
Most women are infected with HIV through vaginal intercourse, and without effective vaccines or microbicides, women who cannot negotiate condom use by their partners remain vulnerable.

Baby "Cured" of HIV Infection
Source: MedicineNet nevirapine Specialty [2013.04.03]
Title: Baby "Cured" of HIV Infection
Category: Doctor's & Expert's views on Symptoms
Created: 4/3/2013 6:12:00 PM
Last Editorial Review: 4/3/2013 6:12:53 PM

more news >>

Published Studies Related to Kaletra (Lopinavir / Ritonavir)

Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteers. [2011.07]
The objective of this investigation was to evaluate the pharmacokinetic interaction of lopinavir/ritonavir (LPV/r) with BILR 355. In group A, 26 healthy participants were administered LPV/r (400mg/100mg) twice daily for 14 days, followed by coadministration of BILR 355, 150 mg twice daily for an additional 7 days...

Beneficial effects of a switch to a Lopinavir/ritonavir-containing regimen for patients with partial or no immune reconstitution with highly active antiretroviral therapy despite complete viral suppression. [2011.06]
The purpose of this study was to determine if switching to an Lopinavir/ritonavir (LPV/r)-containing regimen resulted in greater immune reconstitution in patients with immunologic failure despite complete viral suppression with highly active antiretroviral therapy (HAART)... Switching patients to an LPV/r-containing regimen improved CD4(+) counts in patients with prior immunologic failure, and this may be due to an effect of LPV/r on apoptosis.

Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study. [2011.02]
OBJECTIVES: To examine whether the overall results of the CASTLE study pertain to both genders, we analysed the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir in 277 female and 606 male patients in the open-label, multinational trial over 96 weeks. The trial is registered with ClinicalTrials.gov, number NCT00272779... CONCLUSIONS: Once-daily atazanavir/ritonavir is an effective and well-tolerated therapeutic option for women and men with HIV-1 infection. The sex-based differences in response may be due to higher discontinuation rates in women.

The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants. [2011.02]
S/GSK1349572 is an unboosted, once-daily integrase inhibitor with a novel resistance profile. As standard of care for patients infected with HIV is combination therapy, the potential interaction between S/GSK1349572 and ritonavir-boosted protease inhibitors was evaluated... The most frequent drug-related AEs were diarrhea, dizziness, and headache.

Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial. [2011.01.01]
Given the decline in mortality among HIV-infected patients, it has become increasingly important to consider delayed disease-related and/or anti-HIV therapy-related adverse effects, such as lipodystrophy, when choosing initial therapy. Data from the MONARK trial allowed for comparison of the potential lipodystrophic effects of lopinavir/ritonavir (LPV/r) monotherapy with those of triple therapy with LPV/r plus zidovudine (ZDV) and lamivudine (3TC)...

more studies >>

Clinical Trials Related to Kaletra (Lopinavir / Ritonavir)

A Comparison Study of Kaletra Soft-Gel Capsules and Kaletra Tablets in an African American Cohort [Completed]
The purpose of this study is to compare Kaletra tablets with Kaletra soft-gel capsules to see if there is any change in the side effects you may have and to see how people in the study feel about using the tablets.

Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients [Completed]

Lopinavir Capsules to Kaletra or Invirase Tablets [Recruiting]
This study will compare the benefit for patients switching from Kaletra« to Invirase« tablets over remaining on Kaletra« (based on randomization), to elicit the lipid benefits inferred in previous studies

Kaletra: Therapy With Double Protease Inhibitors [Recruiting]
Therapy with Kaletra and one other protease inhibitor in Human Immunodeficiency Virus-patients

Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients [Terminated]
To demonstrate that patients treated with Kaletra have an improvement in their quality of life compared to the quality of life they had with their previous NRTI therapy.

more trials >>

Reports of Suspected Kaletra (Lopinavir / Ritonavir) Side Effects

Foetal Exposure During Pregnancy (238)Maternal Exposure During Pregnancy (134)Premature Baby (90)Stillbirth (61)Abortion Spontaneous (60)Anaemia (49)Diarrhoea (38)Pyrexia (36)Death (36)Atrial Septal Defect (34)more >>


Page last updated: 2014-10-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014